肥胖和基因组:2024年和2025年研究的新兴见解
Lindsey G Yoo1,2, Courtney L Bordelon1,2, David Mendoza1,2
1Adipocyte Biology Laboratory, Pennington Biomedical, Baton Rouge, LA 70808, USA.
Genes
|September 27, 2025
概括
肥胖症涉及除了卡路里摄入之外的遗传和表观遗传因素. 最近的研究表明,脂肪组织和神经通路中的"代谢记忆"影响重量恢复和肥胖风险,指导个性化治疗.
科学领域:
- 肥胖的遗传学和表观遗传学
- 养行为神经生物学
- 代谢调节 代谢调节 代谢调节 代谢调节
背景情况:
- 肥胖是一种由遗传和表观遗传因素影响的复杂流行病,超出了简单的能量平衡.
- 最近的研究表明,脂肪组织中的表观遗传和细胞记忆有助于重量恢复.
- 神经电路中断和代谢变化也在肥胖的持续性中起作用.
研究的目的:
- 审查最近 (过去两年) 肥胖遗传学的进展及其对治疗策略的影响.
- 突出表观遗传和细胞记忆在脂肪组织和神经通路中的作用.
- 探索遗传洞察力如何推动个性化和基于机制的肥胖治疗.
主要方法:
- 对肥胖研究中的最近遗传和表观遗传研究的分析.
- 对全基因组关联研究 (GWAS) 和多基因风险评分 (PRS) 的审查.
- 检查关于突触基因变异和神经细胞信号在养调节中的研究.
主要成果:
- 脂肪组织的表观遗传变化会产生一种"代谢记忆",促进重量恢复.
- 涉及突触蛋白 (例如BSN,APBA1) 和乳毛受体 (GPR75,GPR45) 的神经通路影响养调节.
- GWAS和PRS确定了新的肥胖基点,并预测了针对GLP-1R和GIPR的治疗方法的反应.
结论:
- 肥胖遗传学的进步对于了解疾病的持续性至关重要.
- 表观遗传和神经机制对肥胖风险和体重恢复有显著的贡献.
- 基因洞察力正在为个性化和基于机制的抗肥胖治疗铺平道路.
相关概念视频
01:24Obesity
1.1K
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.1K
02:02Genomics
39.6K
Genomics is the science of genomes: it is the study of all the genetic material of an organism. In humans, the genome consists of information carried in 23 pairs of chromosomes in the nucleus, as well as mitochondrial DNA. In genomics, both coding and non-coding DNA is sequenced and analyzed. Genomics allows a better understanding of all living things, their evolution, and their diversity. It has a myriad of uses: for example, to build phylogenetic trees, to improve productivity and...
39.6K
01:25Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
247
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
247
03:21Genome Size and the Evolution of New Genes
3.3K
3.3K
03:21Genome Size and the Evolution of New Genes
9.0K
While every living organism has a genome of some kind (be it RNA, or DNA), there is considerable variation in the sizes of these blueprints. One major factor that impacts genome size is whether the organism is prokaryotic or eukaryotic. In prokaryotes, the genome contains little to no non-coding sequence, such that genes are tightly clustered in groups or operons sequentially along the chromosome. Conversely, the genes in eukaryotes are punctuated by long stretches of non-coding sequence.
9.0K
01:20Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
169
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
169